The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia

S. Aliberti, J. A. Myers, P. Peyrani, F. Blasi, R. Menendez, P. Rossi, R. Cosentini, G. Lopardo, L. De Vedia, J. A. Ramirez

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although the presence of neutropenia may predispose cancer patients to develop community-acquired pneumonia, the role of neutropenia on their outcomes has not been investigated. The purpose of the present study was to compare clinical outcomes of cancer community-acquired pneumonia patients with and without neutropenia. Patients with cancer, identified in the Community-Acquired Pneumonia Organization database, were divided into two groups according to the type of cancer and the presence of neutropenia: patients with solid cancer without neutropenia versus those with functional or absolute neutropenia. Among the 3,106 community-acquired pneumonia patients enrolled, 135 had cancer without neutropenia and 75 had cancer with neutropenia. No significant difference was found between patients with and without neutropenia regarding mean time to clinical stability (5.4±2.7 versus 4.9±2.7 days, respectively), mean length of hospital stay (9.2±7.7 versus 9.9±9.6 days) and in-hospital mortality (18 versus 15%, respectively). Using a multiple logistic regression model, neutropenia was not associated with mortality in cancer patients when adjusting for significant covariates (odds ratio 1.30). Lack of neutropenia, during the initial evaluation of a cancer community-acquired pneumonia patient, should not be considered an indicator of better clinical outcome. Copyright

Original languageEnglish
Pages (from-to)142-147
Number of pages6
JournalEuropean Respiratory Journal
Volume33
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Neutropenia
Pneumonia
Neoplasms
Length of Stay
Logistic Models
Hospital Mortality
Odds Ratio
Organizations
Databases
Mortality

Keywords

  • Cancer
  • Community-acquired pneumonia
  • Neutropenia
  • Outcomes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Aliberti, S., Myers, J. A., Peyrani, P., Blasi, F., Menendez, R., Rossi, P., ... Ramirez, J. A. (2009). The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia. European Respiratory Journal, 33(1), 142-147. https://doi.org/10.1183/09031936.00167707

The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia. / Aliberti, S.; Myers, J. A.; Peyrani, P.; Blasi, F.; Menendez, R.; Rossi, P.; Cosentini, R.; Lopardo, G.; De Vedia, L.; Ramirez, J. A.

In: European Respiratory Journal, Vol. 33, No. 1, 01.2009, p. 142-147.

Research output: Contribution to journalArticle

Aliberti, S, Myers, JA, Peyrani, P, Blasi, F, Menendez, R, Rossi, P, Cosentini, R, Lopardo, G, De Vedia, L & Ramirez, JA 2009, 'The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia', European Respiratory Journal, vol. 33, no. 1, pp. 142-147. https://doi.org/10.1183/09031936.00167707
Aliberti, S. ; Myers, J. A. ; Peyrani, P. ; Blasi, F. ; Menendez, R. ; Rossi, P. ; Cosentini, R. ; Lopardo, G. ; De Vedia, L. ; Ramirez, J. A. / The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia. In: European Respiratory Journal. 2009 ; Vol. 33, No. 1. pp. 142-147.
@article{1f50e8b55f0644038728aa7f4a6d709e,
title = "The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia",
abstract = "Although the presence of neutropenia may predispose cancer patients to develop community-acquired pneumonia, the role of neutropenia on their outcomes has not been investigated. The purpose of the present study was to compare clinical outcomes of cancer community-acquired pneumonia patients with and without neutropenia. Patients with cancer, identified in the Community-Acquired Pneumonia Organization database, were divided into two groups according to the type of cancer and the presence of neutropenia: patients with solid cancer without neutropenia versus those with functional or absolute neutropenia. Among the 3,106 community-acquired pneumonia patients enrolled, 135 had cancer without neutropenia and 75 had cancer with neutropenia. No significant difference was found between patients with and without neutropenia regarding mean time to clinical stability (5.4±2.7 versus 4.9±2.7 days, respectively), mean length of hospital stay (9.2±7.7 versus 9.9±9.6 days) and in-hospital mortality (18 versus 15{\%}, respectively). Using a multiple logistic regression model, neutropenia was not associated with mortality in cancer patients when adjusting for significant covariates (odds ratio 1.30). Lack of neutropenia, during the initial evaluation of a cancer community-acquired pneumonia patient, should not be considered an indicator of better clinical outcome. Copyright",
keywords = "Cancer, Community-acquired pneumonia, Neutropenia, Outcomes",
author = "S. Aliberti and Myers, {J. A.} and P. Peyrani and F. Blasi and R. Menendez and P. Rossi and R. Cosentini and G. Lopardo and {De Vedia}, L. and Ramirez, {J. A.}",
year = "2009",
month = "1",
doi = "10.1183/09031936.00167707",
language = "English",
volume = "33",
pages = "142--147",
journal = "European Journal of Respiratory Diseases",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia

AU - Aliberti, S.

AU - Myers, J. A.

AU - Peyrani, P.

AU - Blasi, F.

AU - Menendez, R.

AU - Rossi, P.

AU - Cosentini, R.

AU - Lopardo, G.

AU - De Vedia, L.

AU - Ramirez, J. A.

PY - 2009/1

Y1 - 2009/1

N2 - Although the presence of neutropenia may predispose cancer patients to develop community-acquired pneumonia, the role of neutropenia on their outcomes has not been investigated. The purpose of the present study was to compare clinical outcomes of cancer community-acquired pneumonia patients with and without neutropenia. Patients with cancer, identified in the Community-Acquired Pneumonia Organization database, were divided into two groups according to the type of cancer and the presence of neutropenia: patients with solid cancer without neutropenia versus those with functional or absolute neutropenia. Among the 3,106 community-acquired pneumonia patients enrolled, 135 had cancer without neutropenia and 75 had cancer with neutropenia. No significant difference was found between patients with and without neutropenia regarding mean time to clinical stability (5.4±2.7 versus 4.9±2.7 days, respectively), mean length of hospital stay (9.2±7.7 versus 9.9±9.6 days) and in-hospital mortality (18 versus 15%, respectively). Using a multiple logistic regression model, neutropenia was not associated with mortality in cancer patients when adjusting for significant covariates (odds ratio 1.30). Lack of neutropenia, during the initial evaluation of a cancer community-acquired pneumonia patient, should not be considered an indicator of better clinical outcome. Copyright

AB - Although the presence of neutropenia may predispose cancer patients to develop community-acquired pneumonia, the role of neutropenia on their outcomes has not been investigated. The purpose of the present study was to compare clinical outcomes of cancer community-acquired pneumonia patients with and without neutropenia. Patients with cancer, identified in the Community-Acquired Pneumonia Organization database, were divided into two groups according to the type of cancer and the presence of neutropenia: patients with solid cancer without neutropenia versus those with functional or absolute neutropenia. Among the 3,106 community-acquired pneumonia patients enrolled, 135 had cancer without neutropenia and 75 had cancer with neutropenia. No significant difference was found between patients with and without neutropenia regarding mean time to clinical stability (5.4±2.7 versus 4.9±2.7 days, respectively), mean length of hospital stay (9.2±7.7 versus 9.9±9.6 days) and in-hospital mortality (18 versus 15%, respectively). Using a multiple logistic regression model, neutropenia was not associated with mortality in cancer patients when adjusting for significant covariates (odds ratio 1.30). Lack of neutropenia, during the initial evaluation of a cancer community-acquired pneumonia patient, should not be considered an indicator of better clinical outcome. Copyright

KW - Cancer

KW - Community-acquired pneumonia

KW - Neutropenia

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=58849140035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849140035&partnerID=8YFLogxK

U2 - 10.1183/09031936.00167707

DO - 10.1183/09031936.00167707

M3 - Article

VL - 33

SP - 142

EP - 147

JO - European Journal of Respiratory Diseases

JF - European Journal of Respiratory Diseases

SN - 0903-1936

IS - 1

ER -